Navigation Links
Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
Date:7/1/2009

EXTON, Penn., July 1 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease.

Under the terms of the agreement, Synageva will use its proprietary Synageva Expression Platform (SEP(TM)) technology and its expertise to produce and develop a therapeutic monoclonal antibody. SEP(TM) is an integrated platform of proprietary systems for protein production, processing and purification.

"Morphotek is an industry leader in antibody discovery and development," said Sanj K. Patel, President and Chief Executive Officer of Synageva BioPharma Corporation. "Their commitment to utilizing Synageva's platform is a testament to the strength of our science and product development capabilities and we are excited about the potential for this collaboration."

"We have a rich pipeline of antibody products such as MORAb-003, or farletuzumab, for ovarian cancer in Phase III, MORAb-009 for pancreatic cancer in Phase II and MORAb-004 that is pan-cancer specific in Phase I," stated Philip M. Sass, PhD, Executive Vice President and Chief Operating Officer, Morphotek, Inc. "We are always exploring new ways that may enhance the manufacturing process for our antibody products as a means to fulfill Eisai's hhc mission."

Through the use of its proprietary MORPHODOMA(R) technology, Morphotek develops optimized antibodies, including antibodies optimized for affinity and/or titer, for therapeutic applications and high-titer manufacturing cell lines. The company has assembled a portfolio of lead human and humanized antibodies to antigens associated with cancer, neovascular, inflammatory and infectious disease. The antibodies within the company's pipeline are targeted against a
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma
2. Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
3. Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 As the ... strong push within the industry to deliver better ... Organizations and pharma companies often means turning big ... Microtablets, developed in collaboration with Sensidose AB and ... can bring products to market sooner. The partnership ...
(Date:5/21/2013)... Emerson Resources Inc. , a ... Signorino, the Company’s Chief Executive Officer and Chairman of ... years of service. As part of Emerson Resources’ planned ... been named as Dr. Signorino’s successor. , Dr. ... having made a significant contribution to the field during ...
(Date:5/21/2013)... , May 21, 2013  Synthetic Biologics, Inc. (NYSE MKT: ... treatment of serious infectious diseases, announced today that ... nd Annual Marcum LLP MicroCap Conference on Thursday, May ... at the Grand Hyatt Hotel. Mr. Riley is scheduled to ... webcast of Synthetic Biologics, presentation can be accessed by logging ...
(Date:5/21/2013)... Bed bugs have become so widespread in the ... turn to chemical-based pesticides for help to completely get rid ... those solutions present, the company advised the public to ... , According to My Cleaning Products, chemical-based pesticides are not ... It shared that the pests have already developed immunity to ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3
... Md., Oct. 28 Sirnaomics, Inc., (http://www.sirnaomics.com ... received an SBIR,(small business innovation research) grant ... Health (NIH). Sirnaomics, Inc., a,biopharmaceutical company founded ... interference (RNAi) Technology for novel targeted therapeutic,development. ...
... N30 Pharma (N30), a,biopharmaceutical company focused on ... nitric oxide bioavailability,announced today that it has completed ... N30 will use proceeds from this financing to ... its discovery and preclinical,research in the area of ...
... Achieves ... Collaboration Milestone, SAN DIEGO, CA - October 28, ... on using proprietary,technologies to discover and develop novel flavor ingredients for ... a payment from The Coca-Cola Company (NYSE: KO ) related ...
Cached Biology Technology:Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics 2Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics 3N30 Pharma Announces Financing, Expansion of Board 2SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 2SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 3
(Date:5/21/2013)... increasingly being considered in the management of natural ... that can help them recognize and respond to ... their lives. , Place-Based Conservation: Perspectives from ... the Pacific Northwest Research Station,s Linda Kruger, can ... The book is published by Springer Verlag and ...
(Date:5/21/2013)... developed a new method for delivering molecules into ... cell surface. The technique could find applications in ... , Bulk electroporation a technique used to ... the cell membrane that are caused by exposing ... popular method of cell transfection. (Cell transfection is ...
(Date:5/21/2013)... Researchers at the University of Illinois at Chicago College of ... and stores fat -- its main energy source -- and ... disease, under a new $2 million, 4-year grant from the ... heart changes how it uses fuel for energy. These changes ... disease and are different in men and women, says E. ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2Do men's and women's hearts burn fuel differently? 2
... of plants. This reveals the yellow and red pigments that ... A research team at Ume's Plant Science Center (UPSC) has now ... plants in the fall. , The research team's findings are ... National Academy of Sciences . , The different pigments in ...
... collected from U.S. restaurant menus dating to the 1850s ... according to a study to be announced at Oceans ... on the History of Marine Animal Populations. , Led ... Galveston, researchers are charting over 150 years of inflation-adjusted ...
... For a person with allergies or asthma, breathing in ... of inhalation by someone sensitive to their effects, these ... passages, producing uncontrollable sneezing, coughing, or extreme shortness of ... from allergy and asthma attacks. , Scientists have long ...
Cached Biology News:Protein behind autumn color splendor identified 2Restaurant seafood prices since 1850s help plot marine harvests through history 2Restaurant seafood prices since 1850s help plot marine harvests through history 3Restaurant seafood prices since 1850s help plot marine harvests through history 4Restaurant seafood prices since 1850s help plot marine harvests through history 5Restaurant seafood prices since 1850s help plot marine harvests through history 6Restaurant seafood prices since 1850s help plot marine harvests through history 7New factor implicated in allergy and asthma attacks 2New factor implicated in allergy and asthma attacks 3
Rabbit polyclonal to 3-Ethynylestradiol ( Abpromise for all tested applications). Antigen: Ethynylestradiol conjugated to BSA....
Antibody specific for histone H3 acetylated at any of the five N-terminal lysine residues. Rabbit polyclonal serum. Antigen: Synthetic peptide derived from histone H3 N-terminal region, mulitpliy...
NuCycl DAPI Kit Application: Flow Cytometry Reactivity: Human...
...
Biology Products: